https://www.selleckchem.com/pr....oducts/sirpiglenasta
The RVSP (40 ± 2 vs. 24 ± 1 mm Hg, respectively; p less then 0.0001), right ventricle hypertrophy index (65 ± 9 and 25 ± 5%, respectively; p less then 0.0001), vascular periadventitial Col I and Col V, smooth muscle cell α-SMA+, fibronexus, IL-6, IL-17, and TGF-β were higher in the MCT group than in the CTRL group. In conclusion, our findings indicate in situ evidence of Col V and IL-6/IL-17 activation in vascular remodeling and suggest that increase of Col V may yield potential therapeutic targets for treating patients with PAH.
Like
Comment
Share
